SEC Comment Letter 0000000000-22-012202 to IGM Biosciences, Inc. (IGMS) (CIK 0001496323)
IGM Biosciences, Inc. (IGMS) (CIK 0001496323)
Date: Nov. 9, 2022 · CIK: 0001496323 · Accession: 0000000000-22-012202
AI Filing Summary & Sentiment
File numbers found in text: 333-268136
Letter
United States securities and exchange commission logo November 9, 2022 Misbah Tahir Chief Financial Officer IGM Biosciences, Inc. 325 E. Middlefield Road Mountain View, CA 94043 Re:IGM Biosciences, Inc. Registration Statement on Form S-3 Filed November 3, 2022 File No. 333-268136 Dear Misbah Tahir: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jennifer Knapp
Show Raw Text
United States securities and exchange commission logo
November 9, 2022
Misbah Tahir
Chief Financial Officer
IGM Biosciences, Inc.
325 E. Middlefield Road
Mountain View, CA 94043
Re:IGM Biosciences, Inc.
Registration Statement on Form S-3
Filed November 3, 2022
File No. 333-268136
Dear Misbah Tahir:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jennifer Knapp